Spotlight on decitabine for myelodysplastic syndromes in Chinese patients.

Qing-Jie Hu, Bao-An Chen, Recent advances in therapy of myelodysplastic syndromes Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology. ,vol. 20, pp. 1522- ,(2012)

Fayez Estephan, Ramon V Tiu, Current and novel therapeutic approaches in myelodysplastic syndromes. The Journal of community and supportive oncology. ,vol. 12, pp. 236- 249 ,(2014) , 10.12788/JCSO.0057

Peter L. Greenberg, Eyal Attar, John M. Bennett, Clara D. Bloomfield, Carlos M. De Castro, H. Joachim Deeg, James M. Foran, Karin Gaensler, Guillermo Garcia-Manero, Steven D. Gore, David Head, Rami Komrokji, Lori J. Maness, Michael Millenson, Stephen D. Nimer, Margaret R. O'Donnell, Mark A. Schroeder, Paul J. Shami, Richard M. Stone, James E. Thompson, Peter Westervelt, NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes Journal of The National Comprehensive Cancer Network. ,vol. 9, pp. 30- 56 ,(2011) , 10.6004/JNCCN.2011.0005

Jianyong Li, Yaoyu Chen, Yu Zhu, Jianfeng Zhou, Yanli Xu, Yan Li, Kang Yu, Ling Pan, Jianmin Wang, Jiahua Ding, Jian Gu, Shanhua Zhou, Jinning Shi, Ming Hong, Ji Xu, Liangqin Pan, Limin Duan, Run Zhang, Sujiang Zhang, Huayuan Zhu, Hua Lu, Peng Liu, Hongxia Qiu, Hanxin Wu, Sixuan Qian, Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Oncotarget. ,vol. 6, pp. 6448- 6458 ,(2015) , 10.18632/ONCOTARGET.3361

Caterina Musolino, Emanuela Sant’Antonio, Giuseppa Penna, Andrea Alonci, Sabina Russo, Angela Granata, Alessandro Allegra, Epigenetic therapy in myelodysplastic syndromes European Journal of Haematology. ,vol. 84, pp. 463- 473 ,(2010) , 10.1111/J.1600-0609.2010.01433.X

Yen-Yi Juo, Xue-Jun Gong, Ankita Mishra, Xiao Cui, Stephen B Baylin, Nilofer S Azad, Nita Ahuja, Epigenetic therapy for solid tumors: from bench science to clinical trials Epigenomics. ,vol. 7, pp. 215- 235 ,(2015) , 10.2217/EPI.14.73

Quteba Ebrahem, Reda Z Mahfouz, Kwok Peng Ng, Yogen Saunthararajah, High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects Oncotarget. ,vol. 3, pp. 1137- 1145 ,(2012) , 10.18632/ONCOTARGET.597

P. Wijermans, M. Lübbert, G. Verhoef, A. Bosly, C. Ravoet, M. Andre, A. Ferrant, Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients Journal of Clinical Oncology. ,vol. 18, pp. 956- 962 ,(2000) , 10.1200/JCO.2000.18.5.956

Richard L. Momparler, Pharmacology of 5-Aza-2'-deoxycytidine (decitabine) Seminars in Hematology. ,vol. 42, ,(2005) , 10.1053/J.SEMINHEMATOL.2005.05.002

Moshe C. Ornstein, Sudipto Mukherjee, Mikkael A. Sekeres, More is better: Combination therapies for myelodysplastic syndromes Best Practice & Research Clinical Haematology. ,vol. 28, pp. 22- 31 ,(2015) , 10.1016/J.BEHA.2014.11.002